Truist Securities Upgrades Evolent Health to Buy, Maintains Price Target to $6

Benzinga · 1d ago
Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and maintains the price target from $6 to $6.